Alimera Sciences Inc

Alimera Sciences — Q1 2016 Earnings Presentation

13 slides from Alimera Sciences's earnings presentation, May 5, 2016

  1. Slide 1: Results Conference Call First Quarter 2016

    Investor Presentation January 2015 Results Conference Call First Quarter 2016 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s ability to close on additional or alternative debt financing by the end of the second quarter of 2016, t

  3. Slide 3: Q1 2016 Highlights

    • First quarter year-over-year revenue growth of 49% to $5.8 million • Strong U.S. account growth continues • March 2016 was strongest ever sales month with revenue of $2.9 million, trends continuing into April Eyes treated with iluvien® In the four countries in which we are commercialized 5,000 Q1

  4. Slide 4: Persistent US Account Growth

    4 © 2016 Alimera Sciences, All Rights Reserved 4 new U.S. accounts in Q1 2016 61 Persistent US Account Growth Continued Market Penetration Driven by Salesforce Execution 3/31/2015 3/31/2016 47 U.S. accounts 363 US accounts

  5. Slide 5: Benefit Investigations on the Rise

    5 © 2016 Alimera Sciences, All Rights Reserved 5 Average Monthly BI’s in Q1 2016 300 Total First Quarter BI’s 900 1Q15 2Q15 3Q15 4Q15 1Q16 Jan Feb Mar Benefit Investigations on the Rise An Indicator of Revenue Growth to Come 395 134 re- verifications 51 PRE- SUBMISSIONS 900 180 Re- Verifications 51

  6. Slide 6: Europe Back on Track

    6 © 2016 Alimera Sciences, All Rights Reserved 6 Europe Back on Track UK achieves month-on-month growth through Q1 Halting decline in sales and marking return to growth Portugal delivers triple unit volume growth Q1 2016 compared to Q1 2015 German unit volume increases 5th consecutive quarter New qu

  7. Slide 7: Partnership Development Driving Market Opportunity

    7 © 2016 Alimera Sciences, All Rights Reserved 7 Partnership Development Driving Market Opportunity Through International Licensing Agreements Middle east agreement with MEAgate Expecting material revenue contribution in 2017 France & Italy Continuing to negotiate on pricing reimbursement

  8. Slide 8: Financial Overview

    Financial Overview Rick Eiswirth, President & CFO

  9. Slide 9: Select Income Statement Data

    9 © 2016 Alimera Sciences, All Rights Reserved 9 Select Income Statement Data ($000’s) Three Months Ended March 31st, 2016 Three Months Ended March 31st, 2015 Revenue $5,801 $3,938 Gross Profit $5,423 $3,655 Gross Margin 93% 93% Net (Loss) From Operations ($8,790) ($10,994) Net (Loss) Applicable to

  10. Slide 10: Select Balance Sheet Data

    10 © 2016 Alimera Sciences, All Rights Reserved 10 Select Balance Sheet Data ($000’s) As of March 31st, 2016 As of December 31st, 2015 Cash & Cash Equivalents $23,940 $31,075 Total Current Assets $37,212 $45,159 Total Assets $62,000 $70,484 Total Current Liabilities $42,408 $39,933 Total Stockholder

  11. Slide 11: Closing Remarks

    Closing Remarks Dan Myers, CEO

  12. Slide 12: Summary

    Summary 12 © 2016 Alimera Sciences, All Rights Reserved 12 Continued long-term growth ILUVIEN® estimated peak sales potential exceeds $400-500 million Target Strategic Market Opportunities Penetrate international near-commercialization opportunities $2 Billion market opportunity Growing with global

  13. Slide 13: Results Conference Call First Quarter 2016

    Investor Presentation January 2015 Results Conference Call First Quarter 2016

Alimera Sciences — Q1 2016 Earnings Presentation on 6ix